1. 1 Session 2. Developing and Maintaining a Formulary

2. Objectives  Define the formulary system concept  Understand basic formulary management principles  Describe the benefits of an effective formulary system  Identify criteria used for selection of medicines  Describe basic pharmaceutical information resources for evaluating medicines

3. Outline (1)  Introduction  Formulary Management Principles  Maintaining a Formulary System  Process for Selecting New Medicines  Selection Criteria for New Medicines  Nonformulary Medicines

4. Outline (2)  Restricted Pharmaceutical Use  International Nonproprietary Pharmaceutical Names  Information Sources for Evaluating New Medicines  Formulary Manual  Activities  Summary

5. Key Definitions  Formulary—A list of medicines approved for use in the healthcare system by authorized prescribers  Formulary manual—The document that describes medicines that are available for use in a hospital or clinic (i.e., indications, dosage, length of treatment, interactions, precautions, and contraindications)  Formulary system—A system of periodically evaluating and selecting medicines for the formulary, maintaining the formulary, and providing information in a suitable manual or list

6. WHO Model Formulary (2004 and 2007)

7. Benefits of an Effective Formulary System (1)  Approved and efficacious medicines that all practitioners will have available for use  Only the most effective and safest products  Medicines have been evaluated systematically  Medicines are chosen and approved to treat the diseases of the region or country  Physicians develop greater experience with fewer medicines

8. Benefits of an Effective Formulary System (2)  Pharmaceutical therapy at lower cost  Ineffective, high-cost medicines will be excluded from system  Availability of most effective medicines leads to fewer visits, improved outcomes, and lower cost  Reduced inventory cost

9. Benefits of an Effective Formulary System (3)  Consistent supply of medicines  Regulating the number of medicines will improve procurement and inventory management  Economies of scale will increase availability of essential medicines  Saving money leads to consistency in purchasing essential medicines which in turn leads to increased availability

10. Benefits of an Effective Formulary System—Summary  SUPPLY  Easier procurement  Lower amount of stocks  Improved quality assurance  Easier dispensing  PATIENT USE  Focused education efforts  Better compliance  Improved availability  PRESCRIBING  More experience with fewer medicines  Irrational alternatives not available  Focused medicine information  ADRs easier to manage  COST  Lower prices, more competition

11. Formulary Management Principles (1)  Select medicines on the basis of need (diseases and conditions that have been identified locally)  Select “medicines of choice”  Maintain a limited number of medicines (avoid duplications)  Use INN (generic) names  Use combination (fixed-dose) products only in specific proven conditions (e.g., tuberculosis)

12. Formulary Management Principles (2)  Use explicit selection criteria that include—  Efficacy and effectiveness  Safety  Quality  Cost  Select medicines that are consistent with national and regional formularies and standard treatment guidelines  Restrict medicines use to appropriate practitioners

13. Maintaining a Formulary  Evaluate new medicine requests and deletions regularly  Conduct a systematic review of therapeutic groups and classes

14. Steps to Add or Delete a New Medicine

15. Steps to Evaluate a Medicine  Compile information resources  Perform evaluation using established criteria  Write medicine monograph describing the evaluation and results  Develop formulary recommendations to present to the DTC  Obtain expert opinion and recommendations  Make a decision at the DTC meeting  Disseminate the results of the evaluation and DTC recommendations

16. Criteria for Evaluating and Selecting Medicines for Formulary (1)  Disease patterns  Efficacy and effectiveness  Safety  Quality (pharmaceutical products and suppliers)

17. Criteria for Evaluating and Selecting Medicines for Formulary (2)  Cost and cost-effectiveness of the medicine  Well-known medicines  Health system personnel and expertise available to manage the medicine  Financial resources available to buy the medicine

18. Nonformulary Medicines  Open formularies  Closed formularies  Management of nonformulary medicines  Limit number of nonformulary medicines  Limit access  Keep a register of all requests for nonformulary medicines (medicine name, quantity, indication)  Review frequently and discuss in DTC meetings

19. Restricted Medicines (1)  Medicines to be used by specific staff or for specific conditions only  Defined and enforced by the DTC  Necessary to control the use of medicines that should only be used by medical staff with specialized skills  Monitor carefully to ensure the appropriate use

20. Restricted Medicines (2)  Examples—  Certain antimicrobials for infectious disease specialists  Antipsychotic medicines for mental health professionals  Antineoplastic products for oncologists and internal medicine specialists

21. International Nonproprietary Names  Trade or brand names  Disadvantages  Nonproprietary or generic names  Advantages in the health care system

22. Information Resources  Primary Resources  Secondary Resources  Tertiary Resources

23. Primary Literature—Examples  British Medical Journal  Lancet  New England Journal of Medicine  Journal of the American Medical Association  Annals of Internal Medicine  American Journal of Health-System Pharmacists (AJHP)

24. Secondary Literature—Examples  Medical letters, newsletters, or bulletins produced by national bodies that monitor medicine efficacy, safety, and cost  Medical Letter (USA), Drug & Therapeutics Bulletin (UK), The International Society of Drug Bulletins  Peer-reviewed journals  Australian Prescriber, Journal Watch, Prescrire  Electronic databases  MEDLINE and EMBASE abstracts  International pharmaceutical abstracts  Cochrane Library abstracts and evaluations

25. Tertiary Source—Examples  Martindale: The Extra Pharmacopoeia  British National Formulary  USP DI Drug Information  American Hospital Formulary Service (AHFS) Drug Information

26. British National Formulary

27. Internet Resources—Examples  MEDLINE  World Health Organization  Centers for Disease Control and Prevention  National Institutes of Health  U.S. Food and Drug Administration  Cochrane Collaboration  Agency for Healthcare Research and Quality

28. Formulary Manual (1)  Listing of formulary medicines  Alphabetical  Therapeutic category  Medicine information section  Generic name  Dose and strengths  Indications, contraindications, precautions  Side effects  Dosage schedule  Instructions, warnings, interactions

29. Formulary Manual (2)  Supplementary information for medicines  Price  Regulatory category  Storage guidelines  Patient counseling information  Labeling information  Brand names and synonyms

30. Formulary Manual (3)  Prescribing and dispensing guidelines  Rational prescribing techniques  Prescription writing principles  Guidelines on quantities to be dispensed  Controlled medicine requirements  ADR reporting requirements  Dispensing guidelines  List of precautionary labels  Medicine interaction tables

31. Formulary Manual (4)  Treatment protocols  IV medication administration guidelines  Medicines used in pregnancy and lactation  Medicines used in renal failure  Poison guidelines  Prescribing for the elderly

32. Formulary Manual (5)  Other components  Metric tables  ADR reporting form  Product quality reporting form  Request form for adding or deleting medicines  Request form to use nonformulary medicines  Abbreviations  Indexes

33. Formulary Manual (6)  Acceptance of a formulary manual requires buy in by—  Opinion leaders  Hospital administration  Senior staff  Professional associations  Manuals must be prepared carefully  Evidenced-based information  Written by experts  Reviewed frequently to be kept up to date

34. Examples of Rational Drug Selection, Delhi, India*  The essential medicines list (EML) was developed by a multidisciplinary group of experts using criteria of efficacy, safety, and cost  Revised EML saved nearly 30% of money which was used for procuring more medicines resulting in an 80% improved availability in health facilities

35. Activity 1. Adding a New Antibiotic to the Formulary  Your DTC received an application to add cefapime to the hospital formulary. See Participants’ Guide for more information about this new drug and its use.  What criteria are necessary to evaluate this medicine for addition to the formulary?  Using the principles of formulary management, what major concerns do you have before adding this medicine to the formulary?  What pharmaceutical information resources would be used to analyze this medicine for the DTC? Which sources would be the most useful?

36. Activity 2. Formulary Management of NSAIDs  Review the list of nonsteroidal anti-inflammatory drugs provided in the Participants’ Guide  Do you think the listed medicines appear logical and well chosen?  How many chemical entities are available on the formulary?  How many NSAID medicines are necessary for a formulary?  What medicines would you recommend to be added or deleted?  What is the best method to list medicines in a formulary? Is this list easy to read and understand?

37. Summary (1)  Formulary management principles  Select medicines on the basis of need (diseases and conditions that have been identified locally)  Select “medicines of choice”  Avoid duplications and use INN (generic) names  Use combination (fixed-dose) products only in specific proven conditions (e.g., TB)

38. Summary (2)  Formulary management principles (con’t)  Evaluate and select new medicines according to agreed-upon explicit criteria (including efficacy, safety, quality, cost)  Ensure consistency between the formulary list and the recommended standard treatment guidelines  Regularly review and update the formulary  Monitor and control the use of nonformulary medicines  Restrict medicines to use by appropriate practitioners

39. Summary (3)  Maintain reliable resources (human, financial, references) for evaluating medicines  Keep the formulary process ethically correct and transparent  Enlist support of key policy makers and influential health professionals to advocate for the DTC and the formulary system